Benchtop magnetic shielding for benchmarking atomic magnetometers

Here, a benchtop hybrid magnetic shield containing four mumetal cylinders and nine internal flexible printed circuit boards is designed, constructed, tested, and operated. The shield is designed specifically as a test-bed for building and operating ultra-sensitive quantum magnetometers. The geometry and spacing of the mumetal cylinders are optimized to maximize shielding efficiency while maintaining Johnson noise $<15$ fT/$\sqrt{}$Hz. Experimental measurements at the shield's center show passive shielding efficiency of $\left(1.0\pm0.1\right){\times}10^6$ for a $0.2$ Hz oscillating field applied along the shield's axis. The nine flexible printed circuit boards generate three uniform fields, which all deviate from perfect uniformity by ${\leq}0.5$% along $50$% of the inner shield axis, and five linear field gradients and one second-order gradient, which all deviate by ${\leq}4$% from perfect linearity and curvature, respectively, over measured target regions. Together, the target field amplitudes are adjusted to minimize the remnant static field along $40$% of the inner shield axis, as mapped using an atomic magnetometer. In this region, the active null reduces the norm of the magnitudes of the three uniform fields and six gradients by factors of $19.5$ and $19.8$, respectively, thereby reducing the total static field from $1.68$ nT to $0.23$ nT.Comment: 8 pages, 9 figures; This work has been submitted to the IEEE for possible publication. Copyright may be transferred without notice, after which this version may no longer be accessibl

A double-blind, randomized clinical trial of dietary supplementation on cognitive and immune functioning in healthy older adults

BACKGROUND: Declining cognitive function is relatively common and increasingly prevalent. Studies have shown that different nutrients (e.g., Ginkgo biloba and vitamin E) appear to be effective at improving memory and concentration, while less is known about their effect on immunity. METHODS: This study investigated the effect of Ginkgo Synergy® plus Choline (n = 33) and OPC Synergy® plus Catalyn® (n = 31) versus placebo (n = 33) in a 6-month, randomized, double-blind trial on cognitive and immune functioning among English-speaking, non-smoking, healthy older adults. The Stroop Color and Word Test, Trail Making Test A and B, Controlled Oral Word Association, Hopkins Verbal Learning, Mini-Mental State Exam, and Digit Symbol were administered at baseline and 3 and 6 months follow-up to assess cognitive functioning. Cytokines and growth factors were measured at baseline and 6 months to assess inflammation and immune functioning. Data were analyzed with linear mixed modeling. RESULTS: No serious adverse events were noted in this study. According to time on the Trail Making Test-B, the Ginkgo Synergy® plus Choline arm showed improvement from baseline to 3 months follow-up (mean difference = 24.2; SE = 6.4; 95% CI: 8.6, 39.7; p = 0.01). On the Controlled Oral Word Association Trial-S, the scores significantly increased for the Ginkgo Synergy® plus Choline arm from baseline to 6 months follow-up (mean difference = 2.1; SE = 0.8; 95% CI: 0.2, 3.9; p < 0.05) and for the OPC Synergy® plus Catalyn® arm from baseline to 3 months follow-up (mean difference = 2.1; SE = 0.8; 95% CI: 0.2, 4.0; p < 0.05). Epidermal growth factor significantly decreased from baseline to 6 months follow-up for the Ginkgo Synergy® plus Choline arm (mean difference = 120.7; SE = 28.4; 95% CI: 62.6, 178.8; p < 0.001). CONCLUSIONS: Our study showed isolated and modest effects of a Ginkgo biloba plus choline-based formula on cognitive and immune functioning among healthy older adults with no history of significant cognitive deficits. Our trial was registered with clinicaltrials.gov (ID: NCT01672359). This study was supported by a grant from Standard Process, Inc

Cardiovascular, endothelial function, and immune markers in response to treatment with a polysaccharide in HIV + adults in a randomized, double-blind placebo-controlled trial

Given the ongoing problems of hypertension and endothelial dysfunction in the HIV population, the primary objective of the study was to assess the cardiovascular, endothelial function, and immune markers in response to rice bran arabinoxylan compound (RBAC) treatment in a sample of HIV adults on antiretroviral therapy (ART). A randomized, double-blind placebo-controlled trial of 6 months was used to execute the study. Forty-seven subjects were enrolled and randomly assigned to one of two study conditions ( =22 RBAC and =25 placebo) for 6 months with assessments at baseline and 3 and 6 months. A multivariate repeated measures analysis of variance model was used to assess the differences between RBAC and placebo groups in cardiovascular (systolic blood pressure), endothelial function (skin blood flow in response to nitric oxide), and immune (CD4 cell count) markers from baseline to 6 months. The effect of treatment (RBAC versus placebo) was significant (Wilks' λ=0.92, F[3, 102]=3.07, =0.03). The effect of time was significant (Wilks' λ=0.10, F[2, 103]=474.6, <0.001). The overall interaction between treatment and time was significant (Wilks' λ=0.92, F[2, 103]=4.58, =0.01). Time contrasts showed that a difference in the overall dependent variable did not occur from baseline to 3 months (F[1, 104]=2.7, =0.10), marginally occurred from baseline to 6 months (F[1, 104]=3.2, =0.08), and was significant from 3 to 6 months (F[1, 104]=6.43, =0.01). The overall significant interaction suggests varying responses in the dependent variables between RBAC and placebo over time, which is being driven by systolic blood pressure, as it decreased in the RBAC group, but increased in the placebo group. In addition, CD4 manifested a non-significant increase from baseline to 3 months then decreased from 3 to 6 months in the RBAC group, whereas it decreased at 3 months followed by a slight increase at 6 months in the placebo group. Skin blood flow in response to nitric oxide improved non-significantly overall in both groups, but worsened from 3 to 6 months in the placebo group. Thus, RBAC treatment may contribute to modest short-term improvements in systolic blood pressure, endothelial function, and CD4 cell count, which could help improve the overall health profile of HIV adults. Persons with HIV on ART suffer disproportionately from hypertension and endothelial dysfunction compared to the non-infected population, and conventional medical therapy does not alleviate these issues. RBAC is a safe, low-risk alternative that may help to improve the overall quality of life of these patients through modest improvements in these biomarkers plus CD4 cell count